Medtronic received information that following the implant of this transcatheter bioprosthetic valve, the patient was noted with bleeding (oozing) from the right groin.The patient was treated with medication resolving the condition.Additional information was received that hypertension was noted the day of implant, related to the procedure.The issue was resolved with medications.No other adverse patient effects were reported.Additional information was received that this core valve was implanted valve-in-valve into a failed biocor surgical aortic valve (sa v) that had been implanted approximately 7.5 years.(b)(4).This report reflects information received by fda in the form of a notification per 803.22 (b)(2).
|